Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Dulaglutide use to improve binge eating behaviors in a person with type 2 diabetes and obesity.

Innocent B, Elmaoued AA, Cowart K, White RT

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists1 Aug 2025Cited by 2 (Europe PMC)

PMID40220283 (opens in a new tab)DOI10.1093/ajhp/zxaf088 (opens in a new tab)PepBankPUB-40220283
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a patient with binge eating disorder, obesity and diabetes, BES score, BMI, weight and binge eating symptoms decreased after dulaglutide initiation.

    In plain wordsIn one patient, binge eating measures, BMI and weight decreased after dulaglutide compared with baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBinge eating and body size measures
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.75 mg once weekly · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Follow-up measurements were obtained 6 weeks after initiation, at which time reductions in the patient's BES score, BMI, weight, and BED symptoms were observed.
    2 context sentences
    Summary · context
    In this case report, we describe use of dulaglutide for treatment of a patient with BED, obesity, and type 2 diabetes mellitus.
    Summary · context
    Following these baseline assessments, dulaglutide 0.75 mg once weekly was initiated to optimize management of the patient's type 2 diabetes.
  2. 02HumanCase report or seriesSafety outcome

    In a patient with binge eating disorder, obesity and diabetes, dulaglutide was well tolerated without adverse drug events.

    In plain wordsIn one patient with binge eating disorder, obesity and diabetes, dulaglutide caused no reported adverse drug events.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAdverse drug events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.75 mg once weekly · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    Moreover, dulaglutide was well tolerated without adverse drug events.
    2 context sentences
    Summary · context
    In this case report, we describe use of dulaglutide for treatment of a patient with BED, obesity, and type 2 diabetes mellitus.
    Summary · context
    Following these baseline assessments, dulaglutide 0.75 mg once weekly was initiated to optimize management of the patient's type 2 diabetes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.